C

Cara Therapeutics
D

CARA

0.30100
USD
-0.00
(-1.31%)
Market Open
Volume
500
EPS
-1
Div Yield
-
P/E
-0
Market Cap
16,511,510
OverviewSignalsIdeasNews
Related Instruments
    A
    ACB
    -0.14500
    (-3.34%)
    4.20000 USD
    C
    CGC
    -0.02500
    (-0.67%)
    3.72000 USD
    C
    CRBP
    -0.950
    (-5.41%)
    16.610 USD
    C
    CRON
    -0.05000
    (-2.43%)
    2.01000 USD
    H
    HEXO
    -0.03000
    (-2.36%)
    1.23000 USD
    T
    TLRY
    -0.04500
    (-3.25%)
    1.34000 USD
    Z
    ZYNE
    0
    (0%)
    0.000000 USD
    More
News

Title: Cara Therapeutics

Sector: Healthcare
Industry: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.